ANGO CFO reports insider purchase of 890 shares at $11.16
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AngioDynamics (ANGO) reported insider activity by its EVP and CFO. A Form 4 shows a purchase of 890 shares of common stock on 10/13/2025 at a price of $11.16 per share, coded “P” for a purchase.
Following the transaction, the reporting person beneficially owns 256,629 shares, held directly. The filing indicates the role as EVP and CFO and confirms the report was filed by one reporting person.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 890 shares ($9,932)
Net Buy
1 txn
Insider
Trowbridge Stephen A
Role
EVP and CFO
Bought
890 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 890 | $11.16 | $10K |
Holdings After Transaction:
Common Stock — 256,629 shares (Direct)
Footnotes (1)
FAQ
What did ANGO's CFO report in this Form 4?
A purchase of 890 shares of common stock on 10/13/2025 at $11.16 per share, transaction code P.
Who is the reporting person and their role at ANGO?
An officer, serving as EVP and CFO.
Was this filing made by one person or a group?
It was filed by one reporting person.
What was the transaction code and what does it indicate?
The code was P, indicating a purchase.
Were any derivative securities involved?
No. Table II shows no derivative securities reported.